Study objective: To prove that Ulipristal acetate is an effective line of management for
uterine fibroids by causing a significant decline in fibroid volumes resulting in a
substantial relief of fibroid-related symptoms, and to compare its results with those of
uterine artery embolization.
Design: A randomized control trial. Setting: Maternity Hospital, Ain Shams University.
Patients: Women with symptomatic uterine fibroids.
Interventions: 70 women were randomly assigned to either Ulipristal Acetate (UA) group or
uterine artery embolization (UAE) group (35 in each group). Both groups were followed up to
detect the decline in fibroid size as well as the improvement of symptoms.